Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)

The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in 2022. For long-term investors, this could represent a huge gift, especially as some of the stocks in this space are also working in new domains and technologies, including psychedelic treatment strategies that may […]

Small Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)

The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in 2022. For long-term investors, this could represent a huge gift, especially as some of the stocks in this space are also working in new domains and technologies, including psychedelic treatment strategies that may […]

Alkermes Q2 Results Beat Estimates, Raises Fiscal 2013 Guidance (ALKS)

Biopharmaceutical company Alkermes (NASDAQ: ALKS) reported a 72% rise in the fiscal 2013 second-quarter revenue compared to the corresponding period of fiscal 2012. For the second quarter, Alkermes reported a net loss that narrowed from the similar period of fiscal 2012. The company improved its fiscal 2013 full year revenue and earnings guidance. The Ireland-based […]